IP for Cancer Gene Therapy at Issue -- A Washington Post article published today looked at US cancer patients who are traveling to China to receive Gendicine, the gene therapy for cancer that is produced by Shenzhen SiBiono GeneTech in China, a company that is majority owned by Benda Pharma (BPMA) (see story). Although the interviewed patients are happy with their treatments - which they must pay for themselves - they are angry that the same medications are not available in the US. More details...